132 related articles for article (PubMed ID: 23900701)
1. Clinical implications of Ezrin and CD44 co‑expression in breast cancer.
Ma L; Jiang T
Oncol Rep; 2013 Oct; 30(4):1899-905. PubMed ID: 23900701
[TBL] [Abstract][Full Text] [Related]
2. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
[TBL] [Abstract][Full Text] [Related]
3. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
[TBL] [Abstract][Full Text] [Related]
4. Impact of CD44+CD24- cells on non-sentinel axillary lymph node metastases in sentinel node-positive breast cancer.
Nogi H; Suzuki M; Kamio M; Kato K; Kawase K; Toriumi Y; Takeyama H; Fukushima H; Morikawa T; Uchida K
Oncol Rep; 2011 Apr; 25(4):1109-15. PubMed ID: 21308353
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Wang Z; Shi Q; Wang Z; Gu Y; Shen Y; Sun M; Deng M; Zhang H; Fang J; Zhang S; Xie F
Pathol Res Pract; 2011 Aug; 207(8):505-13. PubMed ID: 21802218
[TBL] [Abstract][Full Text] [Related]
6. Expression of cancer stem cell markers in basal and penta-negative breast carcinomas--a study of a series of triple-negative tumors.
Uchôa Dde M; Graudenz MS; Callegari-Jacques SM; Hartmann CR; Ferreira BP; Fitarelli-Kiehl M; Edelweiss MI
Pathol Res Pract; 2014 Jul; 210(7):432-9. PubMed ID: 24726267
[TBL] [Abstract][Full Text] [Related]
7. Characteristic genes in luminal subtype breast tumors with CD44+CD24-/low gene expression signature.
Tsunoda Y; Sakamoto M; Sawada T; Sasaki A; Yamamoto G; Tachikawa T
Oncology; 2011; 81(5-6):336-44. PubMed ID: 22237177
[TBL] [Abstract][Full Text] [Related]
8. Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC).
Ma F; Li H; Wang H; Shi X; Fan Y; Ding X; Lin C; Zhan Q; Qian H; Xu B
Cancer Lett; 2014 Oct; 353(2):153-9. PubMed ID: 25130168
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.
Hashimoto K; Shimizu C; Tsuda H; Saji S; Osaki A; Shigekawa T; Aogi K
Oncology; 2012; 82(3):168-74. PubMed ID: 22433454
[TBL] [Abstract][Full Text] [Related]
10. Distribution of CD44/CD24 positive cells in ductal invasive carcinoma of breast of different grade and molecular subtype.
Gudadze M; Kankava K; Mariamidze A; Mosidze T; Burkadze G
Georgian Med News; 2013 Sep; (222):50-7. PubMed ID: 24099815
[TBL] [Abstract][Full Text] [Related]
11. Semi-quantitative evaluation of CD44(+) /CD24(-) tumor cell distribution in breast cancer tissue using a newly developed fluorescence immunohistochemical staining method.
Kai M; Onishi H; Souzaki M; Tanaka H; Kubo M; Tanaka M; Katano M
Cancer Sci; 2011 Dec; 102(12):2132-8. PubMed ID: 21838786
[TBL] [Abstract][Full Text] [Related]
12. CD44(+)/CD24(-) cells are transit progenitors and do not determine the molecular subtypes and clinical parameters in breast carcinomas.
Lü X; Xu K; Lü H; Yin Y; Ma C; Liu Y; Li H; Suo Z
Ultrastruct Pathol; 2011 Apr; 35(2):72-8. PubMed ID: 21299347
[TBL] [Abstract][Full Text] [Related]
13. The clinicopathological significance of CD44+/CD24-/low and CD24+ tumor cells in invasive micropapillary carcinoma of the breast.
Li W; Liu F; Lei T; Xu X; Liu B; Cui L; Wei J; Guo X; Lang R; Fan Y; Gu F; Tang P; Zhang X; Fu L
Pathol Res Pract; 2010 Dec; 206(12):828-34. PubMed ID: 20977976
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer.
Bernardi MA; Logullo AF; Pasini FS; Nonogaki S; Blumke C; Soares FA; Brentani MM
Oncol Rep; 2012 Jan; 27(1):28-38. PubMed ID: 21956537
[TBL] [Abstract][Full Text] [Related]
15. [Expression of ezrin in human non-small cell lung cancer and its relationship with metastasis and prognosis].
Chen QY; Yan J; Hu HZ; Chen FY; Song J; Jiang ZY; Jiao DM; Wu YQ
Zhonghua Zhong Liu Za Zhi; 2012 Jun; 34(6):436-40. PubMed ID: 22967445
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of CD44+/CD24- tumor cell ratio in breast cancer.
Liu C; Luo Y; Liu X; Lu P; Zhao Z
Cancer Biother Radiopharm; 2012 Jun; 27(5):324-8. PubMed ID: 22702496
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
[TBL] [Abstract][Full Text] [Related]
18. Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma.
Köbel M; Gradhand E; Zeng K; Schmitt WD; Kriese K; Lantzsch T; Wolters M; Dittmer J; Strauss HG; Thomssen C; Hauptmann S
Int J Gynecol Pathol; 2006 Apr; 25(2):121-30. PubMed ID: 16633060
[TBL] [Abstract][Full Text] [Related]
19. Expression of E-cadherin, beta-catenin, CD44s and CD44v6 in gastric adenocarcinoma: relationship with lymph node metastasis.
Joo M; Lee HK; Kang YK
Anticancer Res; 2003; 23(2B):1581-8. PubMed ID: 12820426
[TBL] [Abstract][Full Text] [Related]
20. Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma.
Zheng Z; Shao N; Weng H; Li W; Zhang J; Zhang L; Yang L; Ye S
Med Oncol; 2015 Jan; 32(1):275. PubMed ID: 25429827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]